Version 9 Release Notes Version 9 (v9) was released on 14 October 2018. The previous version was v8.0. From this time on, version numbers will increase by single digits (e.g., v9, v10). Earlier updates were divided into minor and major, but at this point in time, it seems reasonable to approach all updates as major updates. Additions and major edits were reviewed by the ICLAC members with the opportunity to vote on changes. Voting ID numbers for v9 additions are: 170208, 170316, 170629, 170829, 171204, 180221, 180418, 180625, and 180903. ----- A. Changes to Preamble and Header/Footer 1. Header: the date was changed to the format “DD MMM YYYY”. 2. Header, Preamble: “list” or “database” were replaced with “ICLAC Register of Misidentified Cell Lines”. ICLAC has decided to refer to the dataset as a Register because adding new cell lines is essentially a process of registration, which includes review of data and voting. 3. Preamble: an additional comment was added that the latest version of the Register is available at http://iclac.org/databases/cross-contaminations/. 4. Preamble: the final sentence was deleted, which previously read “The authors take neither credit nor responsibility for any of the primary observations and have merely attempted to review and collate data previously available on other sites.” ICLAC now tries to investigate cases further where possible, which means that this statement is no longer true. 5. Preamble: the text above Table 1 and Table 2 were merged; the same text is now provided above both tables. 6. Preamble: content was moved to separate lines and rearranged to look better for Excel format. ----- B. Changes to Structure and Format 1. All tables: a new column was added for “Registration ID”. This follows the decision to refer to the list as the “ICLAC Register of Misidentified Cell Lines”. We need to understand when cell lines were added to the Register and on what basis. Adding a unique identifier is intended to improve traceability. The registration ID is for all users. 2. All tables: a new column was added for “Review ID”. Although adding a unique identifier is important, this is a retrospective action and the ID is not included on older documentation. To improve traceability of older entries, the version and voting number (used for ICLAC member input) are also recorded. Review ID is for internal use only. 3. All tables: Registration IDs were added to all cell lines included in the register or reviewed by the ICLAC members. Registration IDs were added sequentially in order of review. 4. All tables: as part of adding Registration IDs, some entries were merged (combined into one entry) or demerged (separated into two separate entries). Comments have been added to explain the reason for each change. ----- C. Changes to Table 1: No Authentic Stock Known Cell Line Change 1. 1-1ras1000 (BALB/3T3 A31-1-1 derivative) Added to Table 1 (ref: 170316). 2. 1-1src (BALB/3T3 A31-1-1 derivative) Added to Table 1 (ref: 170316). 3. 1E8 (BLIN-1 derivative) Comment added to explain why 1E8 and BLIN-1 were originally listed as one entry and are now listed separately. 4. 28SC-ES (SC derivative) Added to Table 1 (ref: 170208). 5. 3AB-OS (MG-63 derivative) Added to Table 1 (ref: 180221). 6. ARO Merged with ARO81-1; the laboratory that supplied ARO to Zhao et al. (2011) confirmed that these are the same cell lines. 7. BALB/3T3 A31-1-1 (1-1, A31-1-1, Balb/c 3T3 A31-I-1; BALB/3T3 A31 derivative) Added to Table 1 (ref: 170316). 8. BALB/3T3 A31-1-13 (Balb/c 3T3 A31-1-13; BALB/3T3 A31 derivative) Added to Table 1 (ref: 170316). 9. BEL-7402 Added to Table 1 (ref: 180418). 10. BEL-7404 Added to Table 1 (ref: 180418). 11. Bhas42 (BALB/3T3 A31-1-1 derivative) Added to Table 1 (ref: 170316). 12. BHP 14-9 Reference added (Korch et al 2018) and comment updated. 13. BHP 15-3 Added to Table 1 (ref: 180625). 14. BHP 17-10 Reference added (Korch et al 2018) and comment updated. 15. BHP 5-15 Reference added (Korch et al 2018) and comment updated. 16. BLIN-1 Comment added to explain why 1E8 and BLIN-1 were originally listed as one entry and are now listed separately. 17. C13 Merged with 2008/C13*5.25. This should have been done in V8.0 as part of reviewing this entry, but was omitted by accident. 18. CGTH-W-1 Added to Table 1 (ref: 170829). 19. CH1-cisR (CH1 derivative) Separated from CH1 for consistency with other entries where derivatives are added separately. 20. COLO-38 Added to Table 1 (ref: 180625). 21. COLO-677 Comment added re testing of early sample (ref: 170829). 22. COLO-775 Added to Table 1 (ref: 170829). 23. Culisita inornata culture Name changed to “Culiseta inornata”; this name reflects the correct species name and fixes a typo. 24. DRO Merged with DRO90-1; the laboratory that supplied DRO to Zhao et al. (2011) confirmed that these are the same cell lines. 25. EL 1 Added to Table 1 (ref: 170208). 26. F2-4E5 Comment added re tissue origin of SK-HEP-1. 27. F2-5B6 Comment added re tissue origin of SK-HEP-1. 28. GR-M Added to Table 1 (ref: 170829). 29. H7D7A Reference to “and derivatives” in the cell line name removed. HepG2 cell type changed from hepatocellular carcinoma to hepatoblastoma. 30. H7D7B Reference to “and derivatives” in the cell line name removed. HepG2 cell type changed from hepatocellular carcinoma to hepatoblastoma. 31. H7D7BD5 (H7D7B derivative) Separated from H7D7B for consistency with other entries where derivatives are added separately. HepG2 cell type changed from hepatocellular carcinoma to hepatoblastoma. 32. H7D7C Reference to “and derivatives” in the cell line name removed. HepG2 cell type changed from hepatocellular carcinoma to hepatoblastoma. 33. H7D7D Reference to “and derivatives” in the cell line name removed. HepG2 cell type changed from hepatocellular carcinoma to hepatoblastoma. 34. HCC60 Added to Table 1 (ref: 170629). 35. JROECL 47 (OE47) Added to Table 1 (ref: 180221). 36. JROECL 50 (OE50) Added to Table 1 (ref: 180221). 37. KPL-1 Reference added (Ben-David et al 2018) and new comment added to explain the background to both references. 38. LLC-15MB Reference added (Korch et al 2018) and comment updated. 39. M4A4 (MDA-MB-435 derivative) Derivatives separated for consistency with other entries. Reference added (Korch et al 2018) and comment edited to provide additional background. 40. M4A4 GFP (MDA-MB-435 derivative) Separated from M4A4 for consistency with other entries where derivatives are added separately. 41. M4A4 LM3-2 GFP (MDA-MB-435 derivative) Separated from M4A4 for consistency with other entries where derivatives are added separately. 42. M4A4 LM3-4 CL16 GFP (MDA-MB-435 derivative) Separated from M4A4 for consistency with other entries where derivatives are added separately. 43. MDA-MB-435 Reference added (Korch et al 2018) and comment updated. 44. MDA-MB-435S (MDA-MB-435 derivative) Separated from MDA-MB-435 for consistency with other entries where derivatives are added separately. 45. MDA-N (MDA-MB-435 derivative) Reference added (Korch et al 2018) and comment updated. 46. MUM2C Moved from More Data Needed to Table 1 (ref: 180625). 47. NCI-H249 Comment added to clarify merging of NCI-H249 and H249 in V8.0. 48. NM2C5 (MDA-MB-435 derivative) Derivative separated for consistency with other entries. Reference added (Korch et al 2018) and comment edited to provide additional background. 49. NM2C5 GFP (MDA-MB-435 derivative) Separated from NM2C5 for consistency with other entries where derivatives are added separately. 50. NPA87 Reference added (Korch et al 2018) and comment updated. 51. OCM-1 Moved from More Data Needed to Table 1 (ref: 180625). 52. OV2008 (A2008) Comment added to clarify merging of OV2008 and A2008 in V8.0. 53. P1-1A3 Comment added re tissue origin of SK-HEP-1. 54. P1-4D6 Comment added re tissue origin of SK-HEP-1. 55. PH Added to Table 1 (ref: 170208). 56. QGY-7701 Added to Table 1 (ref: 180418). 57. QGY-7703 Added to Table 1 (ref: 180418). 58. QSG-7701 Added to Table 1 (ref: 180418). 59. SC (28SC) Added to Table 1 (ref: 170208). 60. SMMC-7721 Added to Table 1 (ref: 180418). 61. SNU-1958 Added to Table 1 (ref: 170829). 62. SU-DHL-7 Added to Table 1 (ref: 180625). 63. SU-DHL-9 Added to Table 1 (ref: 180625). 64. SW-527 Reference added (Leibovitz et al 1979) and reported tissue changed to breast carcinoma based on that reference. 65. SW-598 Reference added (Leibovitz et al 1979) and reported tissue changed to meningioma based on that reference. 66. SW-608 Reference added (Leibovitz et al 1979) and reported tissue changed to astrocytoma based on that reference. 67. SW-613 Reference added (Leibovitz et al 1979) and reported tissue changed to breast carcinoma based on that reference. 68. SW-732 Reference added (Leibovitz et al 1979) and reported tissue changed to cervical carcinoma based on that reference. 69. SW-733 Reference added (Leibovitz et al 1979) and reported tissue changed to bladder carcinoma based on that reference. 70. U-118 MG References added (Bady et al 2012, Allen et al 2016) and new comment added to explain the background to all references. 71. UCDK9B1 Added to Table 1 (ref: 171204). 72. UCDK9B2 Added to Table 1 (ref: 171204). 73. UCDK9B3 Added to Table 1 (ref: 171204). 74. UCDK9B4 Added to Table 1 (ref: 171204). 75. UCDK9B5 Added to Table 1 (ref: 171204). 76. Wong-Kilbourne derivative (WKD) Comment added to clarify merging of Wong-Kilbourne derivative and WKD in V8.0. ----- D. Changes to Table 2: Authentic Stock Known Cell Line Change 1. 1205Lu Moved from More Data Needed table to Table 2; reference added (Brafford et al 2016). 2. NCI-H1339 Added to Table 2 (ref: 170629). 3. OV-1063 Moved from Table 1 to Table 2 (ref: 180903). 4. SUM229PE Added to Table 2 (ref: 180221). 5. U-87 MG (U87MG Uppsala) Added to Table 2 (ref: 170629). 6. VM-CUB-III Moved from Table 1 to Table 2 (ref: 180903); references added (Earl et al 2015 [erratum], Nickerson et al 2017). -----